Articles Authored by Catherine Shaffer
Bioinformatics Tool for Tracking Tumor-Immune Interactions Could Be Useful for Guiding Therapy
A map for discovering immune checkpoints and tumor process interactions is showing potential in identifying new drug targets and personalizing immunotherapy.
The law would require state-regulated health insurance plans to cover biomarker testing for patients when recommended by clinical practice guidelines.
Tibsovo added to a standard two-drug treatment regimen extended event-free survival and reduced treatment failure in patients with IDH1-mutant acute myeloid leukemia.
Tissue-Based Drug Screening Platform Shows Potential to Improve Precision Brain Tumor Treatment
In a study by UNC researchers, all brain tumor samples grown on rat brain slices engrafted successfully and retained significant genetic similarity to the parent tumor.
EQRx Slashes Headcount, Pipeline in Corporate 'Reset'
The firm is terminating three licensed programs, cutting 170 positions, seeking partnerships for one drug, and prioritizing development of a CDK4/6 inhibitor.
Amgen's Q1 Revenues Fall 2 Percent Amid Precision Oncology Sales Growth
The drugmaker saw 41 percent growth in sales of Blincyto and 19 percent growth in sales of Lumakras driven by multiple clinical trial readouts.
AstraZeneca Oncology Rx Sales Grow 19 Percent in Q1 as Execs Lay Out Expansion Plans in Lung Cancer
By 2030, the firm is planning to develop new treatments that 50 percent of lung cancer patients will be eligible for.
A score developed using UK Biobank data can identify patients at high and low risk for blood cancer progression and is starting to be used at Dana-Farber Cancer Institute.
Sales from Roche's oncology portfolio grew 4 percent, bolstered by uptake of personalized medicine products Tecentriq and Perjeta.
In presentations at AACR, researchers discussed how drug sensitivity and other functional testing is improving precision oncology amid systemic barriers.